|Mr. Jeffrey Alan Wolf||Founder, Chairman, CEO & Pres||808.23k||N/A||1963|
|Mr. William L. Ostrander||CFO & Sec.||230.62k||N/A||1968|
|Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.||Chief Medical Advisor and Member of Scientific & Clinical Advisory Board||N/A||N/A||N/A|
|Colonel George E. Peoples Jr., F.A.C.S., M.D., FACS||Chief Medical Advisor||N/A||N/A||N/A|
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.